We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03300817
Recruitment Status : Active, not recruiting
First Posted : October 4, 2017
Last Update Posted : February 25, 2022
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.

Condition or disease Intervention/treatment Phase
Lung Carcinoma Other: Laboratory Biomarker Analysis Biological: MUC1 Peptide-Poly-ICLC Vaccine Phase 1

Detailed Description:


I. Immunogenicity of the vaccine, assessed at week 12, based on the increase in IgG anti-MUC1 antibody titer over the pre-vaccination levels.

II. Safety, assessed throughout the trial and continued observation for 24 weeks.


I. To explore potential differences, if any, in the immunogenicity of the vaccine (as assessed at week 12 by the IgG anti-MUC1 antibody titer ratio) in current versus (vs.) former smokers.

II. To evaluate pre-vaccination levels of circulating myeloid derived suppressor cells (MDSC) and correlate with the ability to respond to the vaccine.


I. To explore immune response at week 24. II. To explore the relationship between chronic obstructive pulmonary disease (COPD) status at pre-registration and immune response in current versus former smokers.

III. To explore the impact of the MUC1 peptide-Poly-ICLC vaccine (MUC1/Poly-ICLC vaccine) on inflammation-related high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels.

IV. To explore the impact of baseline levels of hsCRP and IL-6 on the ability to successfully vaccinate with MUC1/Poly-ICLC.

V. To establish a biospecimen repository archive: frozen peripheral blood live cells and plasma for future more detailed and comprehensive immunologic assays, including direct testing of anti-MUC1 T cell immunity.


Patients receive MUC1 peptide-Poly-ICLC vaccine subcutaneously (SC) at weeks 0, 2, and 10.

After completion of study treatment, patients may be followed up at week 28.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
Actual Study Start Date : December 27, 2017
Actual Primary Completion Date : September 23, 2021
Estimated Study Completion Date : December 1, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Prevention (MUC1 peptide-Poly-ICLC vaccine)
Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
Other: Laboratory Biomarker Analysis
Correlative studies

Biological: MUC1 Peptide-Poly-ICLC Vaccine
Given SC

Primary Outcome Measures :
  1. Immunogenicity of the MUC1 vaccine [ Time Frame: At week 12 ]
    Will be evaluated by monitoring changes in IgG anti-MUC1 antibody titer ratio; defined as t12/t0, where t0 is the "initial titer" measured prior to vaccination, and t12 is the "final titer" drawn at 12 weeks. A titer ratio of >= 2 will be considered a positive response.

  2. Incidence of adverse events [ Time Frame: Up to week 24 ]
    Will be assessed according to National Cancer Institute Common Toxicity Criteria version 4.0. The maximum grade for each type of adverse event will be recorded for each participant and frequency tables will be reviewed to determine the overall patterns. In addition, the number and severity of adverse events will be tabulated and summarized across all grades.

Secondary Outcome Measures :
  1. Differences in the immunogenicity of the vaccine [ Time Frame: Up to week 24 ]
  2. Pre-vaccination levels versus post-vaccination levels of circulating myeloid derived suppressor cells (MDSC) [ Time Frame: Up to week 12 ]
    Will correlate with the ability to respond to the vaccine. Will summarize the data using descriptive statistics and graphical methods (i.e. boxplots, scatter plots, etc.). For continuous MDSC data versus response data, will use t-tests or Wilcoxon Rank-Sum tests (for non-normal data). For the associations of 2 continuous variables, will use linear regression, the correlation coefficient, and scatter plots.

Other Outcome Measures:
  1. Chronic obstructive pulmonary disease (COPD) status [ Time Frame: Up to week 24 ]
    Will explore the relationship between COPD status at pre-registration and immune response in current versus former smokers. In individuals with COPD, the severity of airflow obstruction will be measured by the pulmonary function tests as per the GOLD classification.

  2. Changes in immunogenicity in individuals with chronic obstructive pulmonary disease (COPD) [ Time Frame: Baseline up to week 24 ]
    Will explore whether or not changes in immunogenicity in individuals with COPD corresponds to different circulating MDSC levels.

  3. Impact of the MUC1/Poly-ICLC vaccine on inflammation-related high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) [ Time Frame: Up to week 24 ]
  4. Ability to successfully vaccinate with MUC1/Poly-ICLC vaccine depending on baseline high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels [ Time Frame: Up to week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Smoking history of >= 30 pack-years AND either current smoker (still smoking or quit < 1 year prior to pre-registration) OR former smoker (quit 1-15 years prior to pre-registration); Note: Pack years is determined by multiplying the number of packs smoked per day by the number of years smoked
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Computed tomography (CT) scan of the chest done =< 6 months prior to pre-registration showing either negative findings (no nodules) or solid or part-solid nodules < 6 mm in size (consistent with < 1% probability of malignancy, Lung-Reporting and Data Systems [RADs] version 1.0)
  • Willingness to employ adequate contraception, if applicable; Note: women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
  • Ability to understand and the willingness to sign a written informed consent document
  • Leukocytes (white blood cell [WBC]) >= 3,000/microliter
  • Neutrophils (absolute neutrophil count [ANC]) >= 1,500/microliter
  • Platelets >= 100,000/microliter
  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) Note: Higher total bilirubin levels (=< 3 mg/dL) can be allowed if due to known benign liver condition, i.e. Gilbert's
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 1.5 x institutional upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal (ULN)
  • Creatinine =< institutional upper limit of normal (ULN)

Exclusion Criteria:

  • History of any malignancy; exceptions: non-melanoma skin cancer or carcinoma in situ (CIS) of the cervix
  • Known hepatitis B or C
  • Receiving any other investigational agents
  • Any prior investigational immune therapy, such as for lung cancer prevention or treatment or for CIS of the cervix
  • Use of oral or systemic steroids or other systemic anti-immune therapy =< 90 days prior to pre-registration; Note: Use of inhaled/nasal steroids and local steroid injections for pain control are not exclusionary
  • Known human immunodeficiency virus (HIV)
  • Known autoimmune disease
  • Known non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD)
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MUC1/Poly-ICLC
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Any positive antinuclear antibody (ANA) titer above 1:160, even in an asymptomatic individual. Note: Weakly positive ANA defined as ANA titers up to 1:160 maximum (=< 1:160) will be acceptable in an asymptomatic individual who is otherwise eligible for the study
  • Pregnant or breast feeding; Note: Pregnant women are excluded from this study because the MUC1/Poly-ICLC vaccine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with MUC1/Poly-ICLC vaccine, breastfeeding should be discontinued if the mother is treated with the vaccine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03300817

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
United States, Pennsylvania
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Arjun Pennathur Mayo Clinic in Rochester
  Study Documents (Full-Text)

Documents provided by National Cancer Institute (NCI):
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03300817    
Other Study ID Numbers: NCI-2017-01781
NCI-2017-01781 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
MAY2016-08-01 ( Other Identifier: Mayo Clinic in Rochester )
MAY2016-08-01 ( Other Identifier: DCP )
N01CN00042 ( U.S. NIH Grant/Contract )
P30CA015083 ( U.S. NIH Grant/Contract )
First Posted: October 4, 2017    Key Record Dates
Last Update Posted: February 25, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Interferon Inducers
Immunologic Factors
Physiological Effects of Drugs